Opthea Limited announced that it has completed enrollment of all patients in the COAST Phase 3 pivotal clinical trial investigating sozinibercept (OPT-302, a vascular endothelial growth factor (VEGF)-C/D inhibitor) in combination with aflibercept, an anti-VEGF-A therapy, for the treatment of wet Age-related Macular Degeneration (wet AMD). The sozinibercept clinical program includes two Phase 3 pivotal trials, COAST and ShORe. Enrollment in ShORe is expected to be completed in calendar Second Quarter 2024.

Opthea intends to report topline results from these two trials by mid-2025. Completion of patient enrollment in first pivotal trial marks an important milestone in the development of sozinibercept for the treatment of wet AMD.